Igm Biosciences, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.igmbio.com

Market Cap $622.76M
PE -3
Debt $NaN
Cash $43.07M
EV $NaN
FCF -$172.62M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$219.84M
EBIT	-$219.60M
ROE	-278%
ROA	-72%
FCF	-$172.62M
Equity	$78.95M
Growth Stability	1
PE	-2.83
PB	7.89
P/FCF	-3.61
Price/Cash	0.07
Equity CAGR	-10%
Earnings Growth YoY	-1%

Earnings Growth QoQ	28%
Equity CAGR 5Y	-12%
Equity CAGR 3Y	-30%
Market Cap	$622.76M
Assets	$304.51M
Cash	$43.07M
Shares Outstanding	60.4M
Working Capital	185.67M
Current Ratio	5.22
Shares Growth 3y	26%
Equity Growth QoQ	-35%
Equity Growth YoY	-69%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

SEC Filings

Direct access to Igm Biosciences, Inc. (IGMS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Igm Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Igm Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Igm Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Igm Biosciences, Inc..

Years

Calculation mode

= -$1.7B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$173M	-$1.7B
DCF		-$157M	-$143M	-$130M	-$118M	-$107M	-$97M	-$89M	-$81M	-$73M	-$67M	-$666M
Value	-$1.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-	-	-
ROA	-	-573%	-17%	-20%	-55%	-43%	-58%	-72%
ROE	-	35%	-18%	-21%	-67%	-77%	-121%	-278%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-
Earnings YoY growth	-	105%	90%	89%	103%	34%	11%	-
Equity YoY growth	-	63%	-465%	59%	-36%	17%	-29%	-12%
FCF YoY growth	-	94%	128%	79%	62%	-88%	1K%	-